

## Warfarin: the end or the end of one size fits all therapy?

**Munir Pirmohamed,  
University of Liverpool, L69 3GL, UK**

### **Author for correspondence:**

Professor Sir Munir Pirmohamed,  
Wolfson Centre for Personalised Medicine  
Department of Molecular and Clinical Pharmacology,  
University of Liverpool  
Block A: Waterhouse Buildings,  
1-5 Brownlow Street  
Liverpool, L69 3GL  
Phone: 0151 794 5549  
Email: [munirp@liverpool.ac.uk](mailto:munirp@liverpool.ac.uk)

## Abstract

Oral anticoagulants are required for both treatment and prophylaxis in many different diseases. Clinicians and patients now have a choice of oral anticoagulants, including the vitamin K antagonists (of which warfarin is the most widely used, and is used as the exemplar in this paper) and direct oral anticoagulants (DOACs: dabigatran, apixaban, rivaroxaban and edoxaban). The paper explores the recent advances and controversies in oral anticoagulation. While some commentators may favour a complete switchover to DOACs, this paper argues that warfarin still has a place in therapy, and a stratified approach that enables the correct choice of both drug and dose, would improve both patient outcomes and affordability.

## Introduction

Warfarin is more than 60 years old. With the advent of the direct oral anticoagulants (DOACs), some commentators have suggested that the end for warfarin is nigh [1]. However, it may be premature to write an obituary for warfarin, given its widespread use worldwide, and the inability to use warfarin in some patient groups, for example in children, in patients with renal impairment and in patients with heart valves. Furthermore, given the cost of the DOACs, there may still be a place in clinical practice for a stratified approach to anticoagulation. This article examines the history of warfarin use, and in particular, the role of pharmacogenetics, and looking into the future, what still needs to be done to improve the benefit-risk ratio for all oral anticoagulants.

## Warfarin pharmacology and pharmacogenetics

Warfarin is a vitamin K antagonist; it inhibits vitamin K epoxide reductase complex I (VKORC1), preventing the formation of activated vitamin K-dependent coagulation factors II, VII, IX and X [2]. The gene *VKORC1* is polymorphically expressed, which leads to variable expression and activity of the enzyme; for example, the -1639A variant at rs9923231 leads to reduced mRNA levels [3]. Warfarin is administered as a racemate, with the more potent enantiomer *S*-warfarin being metabolised by the P450 isoform CYP2C9 [2]. *CYP2C9* genetic variants show reduced activity; for example *CYP2C9\*3* is associated with a 90% reduction in catalytic activity

of the enzyme [4]. It is interesting to note that the frequencies of both *VKORC1* and *CYP2C9* genetic polymorphisms vary with ethnicity, which has an impact on dose requirement worldwide [5,6] – it is widely acknowledged that African patients generally require higher doses than Caucasians while Chinese patients require lower doses.

There is no argument that warfarin is an effective drug for the treatment of venous thromboembolism, and for prophylaxis against strokes in patients with atrial fibrillation [7]. However, warfarin is also associated with bleeding, estimated to be about 7.2 events per 100 years [8]. Indeed, warfarin is amongst the top 3 drugs responsible for adverse drug reaction related hospital admissions [9]. The major issue with warfarin is the inability to predict inter-individual variability in daily dose requirements. Some patients require 0.5mg per day to maintain therapeutic anticoagulation, for example, an INR between 2 and 3 in the treatment of atrial fibrillation, while others may require 20mg per day, variability of more than 40-fold. We have known for many decades that this variability is partly dependent on clinical factors, such as age, BMI, drug-drug interactions, and concomitant diseases [2]. However, apart from age, none of these clinical predictors have routinely been utilised in dosing regimens.

In order to improve the predictability of daily warfarin dose requirements, many groups worldwide have evaluated the role of genetic and clinical factors. These studies have consistently shown that genetic polymorphisms in *CYP2C9* and *VKORC1* account for a greater degree of variance in daily dose requirement compared with clinical factors such as age, BMI and interactions with drugs such as amiodarone [10,11]. Indeed, the association of warfarin dose requirement with genetic factors is one of the most highly replicated genotype-phenotype associations. Another genetic factor associated with warfarin dose requirement is the *CYP4F2* genetic variant at rs2108622 (*V433M*) [12], the effect being due to differential vitamin K hydroxylation [13]. However, the overall effect size of *CYP4F2* is much lower than that of *CYP2C9* and *VKORC1*, accounting for about 1% of the variability in warfarin dose requirement [14].

One of the most important developments in warfarin pharmacogenetics was the formation of the International Warfarin Pharmacogenetics Consortium (IWPC) that brought together 21 research groups from nine countries and four continents, with analysable data from about 5000 patients [15]. The IWPC developed clinical and genetic warfarin dosing algorithms. The

genetic dosing algorithm was superior to the clinical dosing algorithm, with the greatest benefit being observed in about half of the patients who required either less than 21mg of warfarin per week, or more than 49mg/week.

An important next step in the demonstration of the utility of genotype-guided dosing for warfarin was to demonstrate whether the genetic algorithm was superior to either standard care or a clinical algorithm. A number of clinical trials had already been conducted in this area with variable designs and disparate sample sizes, with inconclusive findings [16]. Because of this, two larger RCTs were undertaken, one in the US (COAG) [17], and another in the EU (EU-PACT) [18]. There were numerous differences in the design of the two trials [16], with COAG comparing a clinical algorithm to a genetic algorithm, while EU-PACT compared standard care in two European countries (UK and Sweden) to the genetic algorithm. Unfortunately, but perhaps not surprisingly given the differences in trial design, the results of the two trials were starkly different, with EU-PACT showing superiority of the genetic algorithm over the comparator arm [19], while in COAG there was no difference between the test and control arms [20]. This led to confusion and criticisms of both trials, and the conclusion that pharmacogenetic dosing of warfarin was not clinically useful [21,22]. Perhaps, this is consistent with the recent paper in *Science* which highlighted that negative stories are more likely to get traction when compared with positive news [23]. Interestingly, following the publication of the trials, it was also suggested that dosing should be based on a clinical algorithm, rather than the standard dosing currently used in clinical care, despite the fact that there has been no RCT that has compared a clinical algorithm to standard of care. This is perhaps another example of genetic exceptionalism, where a lower burden of proof is considered acceptable for non-genetic interventions, when compared with genetic testing. In retrospect, it would have been better to conduct 3-armed trials where genotype-guided dosing was compared simultaneously with both a clinical algorithm and standard dosing.

The reasons for the different outcomes in the two trials have been widely debated, and included differences in algorithms, differences in the comparator arms and greater ethnic heterogeneity in COAG compared with EU-PACT [16]. The design of any algorithm is of course crucial, and it must take into account the ethnic heterogeneity (including the relevant ethnic-specific SNPs) and the known pharmacology of warfarin including its long half-life. It is also

fair to state that no algorithm is perfect, because not all factors that determine warfarin dosing have been identified [10]. The algorithms also predict extreme doses less efficiently (i.e. low or high daily warfarin doses) [15,24]. Algorithms designed for African-American, Indian and Chinese patients have been developed but have not been tested in clinical trials [25-27].

More recently, the GIFT trial has been published [28], conducted in 1650 randomised patients. This used a composite primary outcome measure comprising major bleeding, INR of 4 or greater, venous thromboembolism, or death. The trial found that 10.8% of the genotype-guided group met at least one of the end-points compared with 14.7% in the clinically guided warfarin group, a 27% improvement in favour of genotype guided dosing. The results are consistent with EUPACT [19], but GIFT has the advantage of having included clinical outcomes as part of the primary end. point. Indeed, EUPACT and COAG were both criticised for having used percentage time in therapeutic range (%TTR), a surrogate measure, as the primary outcome measure [22]. Of course, a trial that used only clinical events (thromboembolic or bleeding) as the primary outcome would be preferable but would have required a sample size close to 20,000 patients. It is also important to note that an improvement in %TTR greater than 10% can lead to a 20% improvement in clinical outcomes [29].

From the EU-PACT trial data, it has been shown that genotyping prior to warfarin prescription would be cost effective in both the UK and Sweden [30]. Data on cost-effectiveness from other healthcare systems is awaited [31]. The 2017 Clinical Pharmacology Implementation Consortium (CPIC) guideline on warfarin provides detailed guidance on dosing in patients with variant alleles, including race-specific recommendations [32]. The Dutch Pharmacogenetic Working Group has also developed guidelines for dosing of vitamin K antagonists, and there is a high overall rate of concordance between guidelines produced by the Dutch group and CPIC [33].

### **Direct oral anticoagulants**

Oral anticoagulants acting via the Vitamin K-dependent pathway were the only choices available for clinicians until recently. The introduction of direct acting oral anticoagulants (DOACs) has provided greater choice for both clinicians and patients. These drugs act by

inhibiting either thrombin (dabigatran) or factor Xa (apixaban, rivaroxaban, edoxaban). Large randomised controlled trials in AF and venous thromboembolism have shown that DOACs are either non-inferior or superior to warfarin, with a reduced risk of intracranial haemorrhage, but with a possibly increased risk of gastro-intestinal bleeding [34].

DOACs have been marketed on the basis that "one-dose-fits-all" and that no monitoring is required. There has been rapid uptake of these drugs particularly in western countries, while the use of warfarin has declined [1]. This may well herald the beginning of the end for warfarin, but I feel this is premature for several reasons.

First, although the new DOACs have been shown to be cost-effective [35], there are concerns about the cost outlay given the large population that needs to be treated. It has been estimated that there are 8.8 million people with AF in the European Union and this will double to 17 million in 2060 [36]. In the UK, it has been estimated that expenditure on DOACs may top £1 billion per year by 2020, about 5% of the overall spend on drugs in the NHS [37]. One possible method to improve affordability and ensure all patients have access to oral anticoagulation would be to stratify treatment according to genotypes for *CYP2C9* and *VKORC1*. The evidence for this comes from analyses of the warfarin arm in the edoxaban ENGAGE AF-TIMI 48 trial [38]. This showed that edoxaban reduced the risk of bleeding in those patients who carried variant alleles for *CYP2C9* and/or *VKORC1* such that they were classified as sensitive or highly sensitive responders, when compared with normal responders who represent 62% of the population. A more recent analysis of the Hokusai-venous thromboembolism trial [39] has replicated this finding, showing that sensitive and highly sensitive responders spent more time over-anticoagulated and had a higher bleeding risk compared with normal responders (who represented 63% of the population). Thus, it may be possible to personalise the use of oral anticoagulants in the future so that patients with the low risk genotypes (i.e. normal responders, at least 60%) would get warfarin, while those classified as sensitive or highly sensitive would get DOACs. This would lead to significant savings in expenditure [37], without any compromise in clinical outcomes.

An important issue to consider for taking forward the stratification approach is whether it is possible to implement warfarin genotyping in a clinical setting. Following the EU-PACT trial [19], and despite the conflicting results with COAG [20], we have undertaken an

implementation study. The premise behind the study was to determine whether staff running anticoagulant clinics (predominantly qualified nurses) could modify the current clinical pathway so that genotyping, and subsequent genotype-guided dosing, could be incorporated. This required an improvement in the point-of-care genotyping assay. In EU-PACT, the point-of-care genotyping platform was able to provide results on 3 alleles (*CYP2C9\*2*, *CYP2C9\*3*, and *VKORC1*) in 2 hours [19]. For the implementation study, the platform was modified to provide results within 45 minutes. The results of the implementation study (unpublished) were equivalent to those of our EU-PACT RCT demonstrating that long and well-established clinical pathways could be modified using new technologies.

Second, an unintended consequence of the "no or minimal monitoring" strategy adopted for DOACs may be poor adherence. Our recent data suggest that adherence to DOACs was significantly worse when compared with warfarin [37]. Although INR monitoring is disliked by both patients and clinicians, it does act as a positive reinforcement for patients to continue taking warfarin. It is important to note that there has also been criticism of the "one-dose-fits all" strategy for DOACs, with some patients having been shown to be under-dosed, while others may be over-dosed [40]. Pharmacogenomic studies have identified some associations with plasma concentrations of these drugs, but none of these are likely to be useful in improving the clinical use of these drugs [41,42]. It has been argued that plasma therapeutic drug monitoring should be utilised [43], especially in high-risk patients to individualise dose. High-risk groups could include patients at high risk of bleeding, those on drugs likely to interact with DOACs, and patients with borderline renal impairment, to name a few. Clearly, this would lead to a loss of the marketing advantage for DOACs, and increase cost and inconvenience for patients, and may thus face an uphill battle for implementation.

Third, there are some patients where DOACs are not used because of contra-indications, no marketing authorisation or unaffordability. In these situations (outlined below), warfarin remains the only alternative.

(a) **Patients with renal impairment:** all the drug labels for DOACs have criteria which either recommend a dose reduction, or absolutely contraindicate the use of the DOAC [44]. While it may be relatively easy to avoid the use of DOACs in patients with severe forms of renal impairment, a group that may be at particular risk are patients with incipient renal

impairment, where there may be incipient decline in renal function with age, or an acute decline in an elderly patient because of a concomitant urinary tract infection. This is compounded by the fact that monitoring of renal function in patients on DOACs is poorly performed.

(b) **Patients on interacting drugs:** Although DOACs are less likely to be involved in drug-drug interactions than warfarin, they are not immune from them. For patients on certain medications, for example itraconazole, the use of apixaban is not recommended. A recent database study from Taiwan showed that concomitant use of drugs such as amiodarone, fluconazole, rifampicin, and phenytoin increased the risk of major bleeding when compared with the use of DOACs alone [45]. There is no simple biomarker that can be used to individualise dosing with DOACs, unlike warfarin, where INR monitoring provides the opportunity to change dose to maintain the INR within a therapeutic range.

(c) **Use in children:** DOACs are currently not licensed for use in children, but there are paediatric investigation plans in place [46]. Thus, for the time being, warfarin (or other vitamin K antagonists) remain the only alternatives. There have been numerous studies in children investigating the effects of genetic polymorphisms on warfarin dosing [47-50], but no algorithm has been tested in clinical trials.

(d) **Mechanical heart valves:** DOACs are currently contra-indicated in patients with mechanical heart valves. In the RE-ALIGN trial, after enrolment of 252 patients, an increased risk of bleeding and thrombosis was seen in patients on dabigatran, compared with warfarin, which resulted in premature discontinuation of the trial [51].

Fourth, because of the cost of DOACs, their uptake in developing countries has been low, and thus warfarin (or other vitamin K antagonists) remain the main choice. Unfortunately, genetic and clinical factors affecting warfarin dose variation have been poorly studied in developing countries, and even in developed in minority groups compared with Caucasian populations [6]. The frequencies of genetic variants in *CYP2C9* and *VKORC1* vary with ethnicity. Thus, in Chinese patients *CYP2C9\*2* is less important than in Caucasians [52]. In African-Americans, both *CYP2C9\*2* and *CYP2C9\*3* have a low prevalence, with other variant alleles (*\*8*, *\*11*) being more important [6]. The importance of this was highlighted by the COAG trial [20]



where genotype-guided dosing actually fared worse than clinical dosing in African-American patients. In Africa, where access to medicines and services is limited, warfarin remains the obvious choice of oral anticoagulant. However, dosing regimens are largely empirical and not evidence based, which coupled with the lack of infrastructure leads to poor quality of anticoagulation. For example, in South Africa, a recent study showed that only 28% of patients achieved a therapeutic INR [53]. The importance of achieving better anticoagulation control in developing countries is shown by a study in South Africa which demonstrated that haemorrhage was the fourth most common cause of hospital admission, with warfarin accounting for 68% of the bleeds [54]. We have recently embarked on a large programme of work in Uganda and South Africa (War-PATH: WARfarin anticoagulation in PATients in Sub-Saharan Africa; <http://warpath.info/>), the aim of which is to identify the clinical and genetic factors determining variation in daily warfarin dose requirement and thereby develop better clinical and genetic dosing algorithms to improve anticoagulation quality.

## Conclusions

It has been estimated that the global anticoagulants market will be worth close to \$30billion by 2021 (<https://www.businesswire.com/news/home/20170301005087/en/Increase-Lifestyle-Diseases-Boost-Global-Anticoagulant-Market>). For both clinicians and patients, it is important to have a choice of drugs to use for either treatment or prophylaxis, and the availability of DOACs has certainly provided that choice. However, that does not mean that older drugs have no place in the therapeutic armamentarium, as I have pointed out for warfarin. Undoubtedly, we can continue to improve the benefit-risk ratio of all oral anticoagulants that are available, and a stratified approach to the choice of drug, and the precise dose of that drug (figure 1), may be an option that not only maximises the positive clinical outcomes, but also improves affordability and access. Whether this would be a cost-effective approach would need further study; however, it is clear that the cost-effectiveness of DOACs is reduced or nullified when the quality of anticoagulation with warfarin improves [55], which is likely to be the consequence of a stratified approach.

## Acknowledgements

The author acknowledges the support of the MRC Centre for Drug Safety Science, The NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) North West Coast, the Innovation Agency and the EU FP7 Framework funding programme.

## References

1. Sotiriou, A.; Patel, H.C.; Tyebally, S.; Raza, S.; Qudah, T.; Malik, K.; Patel, K.; Bhattacharyya, S.; Chow, A.; Hayward, C. Is this the beginning of the end for warfarin? *EP Europace* 2017, *19*, i28-i28.
2. Wadelius, M.; Pirmohamed, M. Pharmacogenetics of warfarin: Current status and future challenges. *Pharmacogenomics J* 2007, *7*, 99-111.
3. Rieder, M.J.; Reiner, A.P.; Gage, B.F.; Nickerson, D.A.; Eby, C.S.; McLeod, H.L.; Blough, D.K.; Thummel, K.E.; Veenstra, D.L.; Rettie, A.E. Effect of vkorc1 haplotypes on transcriptional regulation and warfarin dose. *N Engl J Med* 2005, *352*, 2285-2293.
4. Rettie, A.E.; Wienkers, L.C.; Gonzalez, F.J.; Trager, W.F.; Korzekwa, K.R. Impaired (s)-warfarin metabolism catalysed by the r144c allelic variant of cyp2c9. *Pharmacogenetics* 1994, *4*, 39-42.
5. Limdi, N.A.; Wadelius, M.; Cavallari, L.; Eriksson, N.; Crawford, D.C.; Lee, M.T.; Chen, C.H.; Motsinger-Reif, A.; Sagreiya, H.; Liu, N., *et al.* Warfarin pharmacogenetics: A single vkorc1 polymorphism is predictive of dose across 3 racial groups. *Blood* 2010, *115*, 3827-3834.
6. Cavallari, L.H.; Perera, M.A. The future of warfarin pharmacogenetics in under-represented minority groups. *Future cardiology* 2012, *8*, 563-576.
7. Aguilar, M.I.; Hart, R.; Pearce, L.A. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. *Cochrane database of systematic reviews (Online)* 2007, CD006186.
8. Linkins, L.A.; Choi, P.T.; Douketis, J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: A meta-analysis. *Ann Intern Med* 2003, *139*, 893-900.
9. Pirmohamed, M.; James, S.; Meakin, S.; Green, C.; Scott, A.K.; Walley, T.J.; Farrar, K.; Park, B.K.; Breckenridge, A.M. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. *BMJ* 2004, *329*, 15-19.
10. Bourgeois, S.; Jorgensen, A.; Zhang, E.J.; Hanson, A.; Gillman, M.S.; Bumpstead, S.; Toh, C.H.; Williamson, P.; Daly, A.K.; Kamali, F., *et al.* A multi-factorial analysis of response to warfarin in a uk prospective cohort. *Genome medicine* 2016, *8*, 2.
11. Wadelius, M.; Chen, L.Y.; Lindh, J.D.; Eriksson, N.; Ghori, M.J.; Bumpstead, S.; Holm, L.; McGinnis, R.; Rane, A.; Deloukas, P. The largest prospective warfarin-treated cohort supports genetic forecasting. *Blood* 2009, *113*, 784-792.

12. Caldwell, M.D.; Awad, T.; Johnson, J.A.; Gage, B.F.; Falkowski, M.; Gardina, P.; Hubbard, J.; Turpaz, Y.; Langae, T.Y.; Eby, C., *et al.* Cyp4f2 genetic variant alters required warfarin dose. *Blood* 2008, *111*, 4106-4112.
13. Edson, K.Z.; Prasad, B.; Unadkat, J.D.; Suhara, Y.; Okano, T.; Guengerich, F.P.; Rettie, A.E. Cytochrome p450-dependent catabolism of vitamin k: Omega-hydroxylation catalyzed by human cyp4f2 and cyp4f11. *Biochemistry* 2013, *52*, 8276-8285.
14. Danese, E.; Montagnana, M.; Johnson, J.A.; Rettie, A.E.; Zambon, C.F.; Lubitz, S.A.; Suarez-Kurtz, G.; Cavallari, L.H.; Zhao, L.; Huang, M., *et al.* Impact of the cyp4f2 p.V433m polymorphism on coumarin dose requirement: Systematic review and meta-analysis. *Clin Pharmacol Ther* 2012, *92*, 746-756.
15. International Warfarin Pharmacogenetics, C.; Klein, T.E.; Altman, R.B.; Eriksson, N.; Gage, B.F.; Kimmel, S.E.; Lee, M.T.; Limdi, N.A.; Page, D.; Roden, D.M., *et al.* Estimation of the warfarin dose with clinical and pharmacogenetic data. *N Engl J Med* 2009, *360*, 753-764.
16. Pirmohamed, M.; Kamali, F.; Daly, A.K.; Wadelius, M. Oral anticoagulation: A critique of recent advances and controversies. *Trends in pharmacological sciences* 2015, *36*, 153-163.
17. Kimmel, S.E.; French, B.; Anderson, J.L.; Gage, B.F.; Johnson, J.A.; Rosenberg, Y.D.; Geller, N.L.; Kasner, S.E.; Eby, C.S.; Joo, J., *et al.* Rationale and design of the clarification of optimal anticoagulation through genetics trial. *Am Heart J* 2013, *166*, 435-441.
18. van Schie, R.M.; Wadelius, M.I.; Kamali, F.; Daly, A.K.; Manolopoulos, V.G.; de Boer, A.; Barallon, R.; Verhoef, T.I.; Kirchheiner, J.; Haschke-Becher, E., *et al.* Genotype-guided dosing of coumarin derivatives: The european pharmacogenetics of anticoagulant therapy (eu-pact) trial design. *Pharmacogenomics* 2009, *10*, 1687-1695.
19. Pirmohamed, M.; Burnside, G.; Eriksson, N.; Jorgensen, A.L.; Toh, C.H.; Nicholson, T.; Kesteven, P.; Christersson, C.; Wahlstrom, B.; Stafberg, C., *et al.* A randomized trial of genotype-guided dosing of warfarin. *N Engl J Med* 2013, *369*, 2294-2303.
20. Kimmel, S.E.; French, B.; Kasner, S.E.; Johnson, J.A.; Anderson, J.L.; Gage, B.F.; Rosenberg, Y.D.; Eby, C.S.; Madigan, R.A.; McBane, R.B., *et al.* A pharmacogenetic versus a clinical algorithm for warfarin dosing. *N Engl J Med* 2013, *369*, 2283-2293.
21. Zineh, I.; Pacanowski, M.; Woodcock, J. Pharmacogenetics and coumarin dosing-- recalibrating expectations. *N Engl J Med* 2013, *369*, 2273-2275.
22. Furie, B. Do pharmacogenetics have a role in the dosing of vitamin k antagonists? *N Engl J Med* 2013, *369*, 2345-2346.

23. Vosoughi, S.; Roy, D.; Aral, S. The spread of true and false news online. *Science* 2018, *359*, 1146-1151.
24. Saffian, S.; Duffull, S.; Wright, D. Warfarin dosing algorithms underpredict dose requirements in patients requiring  $\geq 7$  mg daily: A systematic review and meta-analysis. *Clinical Pharmacology & Therapeutics* 2017, *102*, 297-304.
25. Wei, M.; Ye, F.; Xie, D.; Zhu, Y.; Zhu, J.; Tao, Y.; Yu, F. A new algorithm to predict warfarin dose from polymorphisms of cyp4f2, cyp2c9 and vkorc1 and clinical variables: Derivation in han chinese patients with non valvular atrial fibrillation. *Thrombosis and haemostasis* 2012, *107*, 1083-1091.
26. Gaikwad, T.; Ghosh, K.; Avery, P.; Kamali, F.; Shetty, S. Warfarin dose model for the prediction of stable maintenance dose in indian patients. *Clinical and Applied Thrombosis/Hemostasis* 2018, *24*, 353-359.
27. Kubo, K.; Ohara, M.; Tachikawa, M.; Cavallari, L.H.; Lee, M.T.M.; Wen, M.S.; Scordo, M.G.; Nutescu, E.A.; Perera, M.A.; Miyajima, A., *et al.* Population differences in s-warfarin pharmacokinetics among african americans, asians and whites: Their influence on pharmacogenetic dosing algorithms. *The Pharmacogenomics Journal* 2016, *17*, 494.
28. Gage, B.F.; Bass, A.R.; Lin, H.; Woller, S.C.; Stevens, S.M.; Al-Hammadi, N.; Li, J.; Rodriguez, T., Jr.; Miller, J.P.; McMillin, G.A., *et al.* Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: The gift randomized clinical trial. *JAMA* 2017, *318*, 1115-1124.
29. Van Spall, H.G.C.; Wallentin, L.; Yusuf, S.; Eikelboom, J.W.; Nieuwlaat, R.; Yang, S.; Kabali, C.; Reilly, P.A.; Ezekowitz, M.D.; Connolly, S.J. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries. An analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (re-ly) trial. *Circulation* 2012, *126*, 2309-2316.
30. Verhoef, T.I.; Redekop, W.K.; Langenskiold, S.; Kamali, F.; Wadelius, M.; Burnside, G.; Maitland-van der Zee, A.H.; Hughes, D.A.; Pirmohamed, M. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the united kingdom and sweden. *The pharmacogenomics journal* 2016, *16*, 478-484.
31. Plumpton, C.O.; Roberts, D.; Pirmohamed, M.; Hughes, D.A. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. *PharmacoEconomics* 2016, *34*, 771-793.
32. Johnson, J.A.; Caudle, K.E.; Gong, L.; Whirl-Carrillo, M.; Stein, C.M.; Scott, S.A.; Lee, M.T.; Gage, B.F.; Kimmel, S.E.; Perera, M.A., *et al.* Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. *Clinical pharmacology and therapeutics* 2017, *102*, 397-404.

33. Bank, P.C.D.; Caudle, K.E.; Swen, J.J.; Gammal, R.S.; Whirl-Carrillo, M.; Klein, T.E.; Relling, M.V.; Guchelaar, H.J. Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group. *Clin Pharmacol Ther* 2018, *103*, 599-618.
34. Ruff, C.T.; Giugliano, R.P.; Braunwald, E.; Hoffman, E.B.; Deenadayalu, N.; Ezekowitz, M.D.; Camm, A.J.; Weitz, J.I.; Lewis, B.S.; Parkhomenko, A., *et al.* Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. *Lancet* 2014, *383*, 955-962.
35. Lopez-Lopez, J.A.; Sterne, J.A.C.; Thom, H.H.Z.; Higgins, J.P.T.; Hingorani, A.D.; Okoli, G.N.; Davies, P.A.; Bodalia, P.N.; Bryden, P.A.; Welton, N.J., *et al.* Oral anticoagulants for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis, and cost effectiveness analysis. *BMJ* 2017, *359*, j5058.
36. Barra, S.; Fynn, S. Untreated atrial fibrillation in the united kingdom: Understanding the barriers and treatment options. *Journal of the Saudi Heart Association* 2015, *27*, 31-43.
37. Burn, J.; Pirmohamed, M. Direct oral anticoagulants versus warfarin: Is new always better than the old? *Open Heart* 2018, *5*, e000712.
38. Mega, J.L.; Walker, J.R.; Ruff, C.T.; Vandell, A.G.; Nordio, F.; Deenadayalu, N.; Murphy, S.A.; Lee, J.; Mercuri, M.F.; Giugliano, R.P., *et al.* Genetics and the clinical response to warfarin and edoxaban: Findings from the randomised, double-blind engage af-timi 48 trial. *Lancet* 2015, *385*, 2280-2287.
39. Vandell, A.G.; Walker, J.; Brown, K.S.; Zhang, G.; Lin, M.; Grosso, M.A.; Mercuri, M.F. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism. *Heart* 2017, *103*, 1800.
40. Gulilat, M.; Tang, A.; Gryn, S.E.; Leong-Sit, P.; Skanes, A.C.; Alfonsi, J.E.; Dresser, G.K.; Henderson, S.L.; Rose, R.V.; Lizotte, D.J., *et al.* Interpatient variation in rivaroxaban and apixaban plasma concentrations in routine care. *Can J Cardiol* 2017, *33*, 1036-1043.
41. Asic, A.; Marjanovic, D.; Mirat, J.; Primorac, D. Pharmacogenetics of novel oral anticoagulants: A review of identified gene variants & future perspectives. *Per Med* 2018, *15*, 209-221.
42. Tseng, A.S.; Patel, R.D.; Quist, H.E.; Kekic, A.; Maddux, J.T.; Grilli, C.B.; Shamoun, F.E. Clinical review of the pharmacogenomics of direct oral anticoagulants. *Cardiovasc Drugs Ther* 2018, *32*, 121-126.
43. Powell, J. Are new oral anticoagulant dosing recommendations optimal for all patients? *JAMA* 2015, *313*, 1013-1014.

44. Lutz, J.; Jurk, K.; Schinzel, H. Direct oral anticoagulants in patients with chronic kidney disease: Patient selection and special considerations. *Int J Nephrol Renovasc Dis* 2017, *10*, 135-143.
45. Chang, S.; Chou, I.; Yeh, Y.; et al. Association between use of non-vitamin k oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. *JAMA* 2017, *318*, 1250-1259.
46. Newall, F.; Branchford, B.; Male, C. Anticoagulant prophylaxis and therapy in children: Current challenges and emerging issues. *J Thromb Haemost* 2018, *16*, 196-208.
47. Biss, T.; Hamberg, A.K.; Avery, P.; Wadelius, M.; Kamali, F. Warfarin dose prediction in children using pharmacogenetics information. *Brit J Haematol* 2012, *159*, 106-109.
48. Vear, S.I.; Stein, C.M.; Ho, R.H. Warfarin pharmacogenomics in children. *Pediatric blood & cancer* 2013, *60*, 1402-1407.
49. Hamberg, A.-K.; Wadelius, M. Pharmacogenetics-based warfarin dosing in children. *Pharmacogenomics* 2014, *15*, 361-374.
50. Hawcutt, D.B.; Ghani, A.A.; Sutton, L.; Jorgensen, A.; Zhang, E.; Murray, M.; Michael, H.; Peart, I.; Smyth, R.L.; Pirmohamed, M. Pharmacogenetics of warfarin in a paediatric population: Time in therapeutic range, initial and stable dosing and adverse effects. *Pharmacogenomics J* 2014, *14*, 542-548.
51. Eikelboom, J.W.; Connolly, S.J.; Brueckmann, M.; Granger, C.B.; Kappetein, A.P.; Mack, M.J.; Blatchford, J.; Devenny, K.; Friedman, J.; Guiver, K., et al. Dabigatran versus warfarin in patients with mechanical heart valves. *New England Journal of Medicine* 2013, *369*, 1206-1214.
52. Lee, M.T.; Klein, T.E. Pharmacogenetics of warfarin: Challenges and opportunities. *J Hum Genet* 2013, *58*, 334-338.
53. Zuhlke, L.; Engel, M.E.; Karthikeyan, G.; Rangarajan, S.; Mackie, P.; Cupido, B.; Mauff, K.; Islam, S.; Joachim, A.; Daniels, R., et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: The global rheumatic heart disease registry (the remedy study). *Eur Heart J* 2015, *36*, 1115-1122a.
54. Mouton, J.P.; Njuguna, C.; Kramer, N.; Stewart, A.; Mehta, U.; Blockman, M.; Fortuin-De Smidt, M.; De Waal, R.; Parrish, A.G.; Wilson, D.P., et al. Adverse drug reactions causing admission to medical wards: A cross-sectional survey at 4 hospitals in south africa. *Medicine (Baltimore)* 2016, *95*, e3437.
55. Pink, J.; Lane, S.; Pirmohamed, M.; Hughes, D.A. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in uk context: Quantitative benefit-harm and economic analyses. *Bmj* 2011, *343*, d6333.

## Figure 1

Clinical pathways for stratification in the use of oral anticoagulants. Use of either warfarin or a direct oral anticoagulant (DOAC) would require individualisation of dose to improve time in therapeutic range, and optimisation of anticoagulation, resulting in improved clinical outcomes. This would also result in increased affordability.